** Shares of Cognition Therapeutics CGTX.O rise 76.7% to 81 cents premarket
** Drug developer says its experimental oral drug, CT1812, met the main goal of safety and tolerability in a mid-stage study
** The study enrolled 130 patients with mild-to-moderate dementia with Lewy bodies - a type of dementia that affects thinking, movement, behavior, and mood
** Co says "patients treated with CT1812 for six months experienced improvement in behavioral, functional, cognitive and movement measures compared to placebo"
** Adds, "there was a marked reduction in caregiver distress, which suggests a positive impact on the day-to-day lives of those receiving the drug"
** Says detailed data will be presented at a medical conference in January 2025
** Says expediting plans to advance CT1812 into late-stage trials
** Up to last close, stock down 75.4% YTD
(Reporting by Sneha S K in Bengaluru)
((Sneha.SK@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。